Publication | Open Access

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19

Hematological MalignancyLymphoid NeoplasiaHealth SciencesMedicineImmunologyHematologyLow-dose Recombinant Interleukin-2ImmunotherapyOncologyRadiation OncologyAdult T-cell Leukemia-lymphomaContinuous InfusionLow-grade Non-hodgkin